N. SankuntawS. ChantarangsuW. ChantratitaS. SungkanuparphS. KiertiburanakulV. LulitanondKhon Kaen UniversityChulalongkorn UniversityMahidol University2018-11-092018-11-092014-01-01Journal of Clinical Pharmacy and Therapeutics. Vol.39, No.5 (2014), 545-55013652710026947272-s2.0-84906763426https://repository.li.mahidol.ac.th/handle/20.500.14594/34711What is known and objective Abacavir (ABC) is a commonly used nucleoside reverse-transcriptase inhibitor with potent antiviral activity against HIV-1. The US Food and Drug Administration and international HIV treatment guidelines recommend HLA-B 57:01 screening before initiating treatment with ABC. The current standard method for HLA-B 57:01 screening is limited by its high-cost, time-consuming and labour-intensive procedure with the requirement of a specialized laboratory. Our study aims to develop a more reliable screening test by selecting rs3093726 as an additional single nucleotide polymorphism (SNP) to combine with rs2395029 for multiplex pyrosequencing development. It offers high-accuracy, cost-effective and rapid detection. Methods Multiplex pyrosequencing was developed for HLA-B 57:01 screening using rs2395029 and rs3093726 as a surrogate marker and tested in 130 Thai subjects in parallel with singleplex pyrosequencing of each SNP and the standard sequence-based method. Results and discussion Multiplex pyrosequencing showed 100% concordance when compared with both singleplex pyrosequencing and standard sequence-based method. This method showed 100% of negative predictive value (NPV), positive predictive value (PPV), specificity and sensitivity. What is new and conclusion Multiplex pyrosequencing is a powerful tool for HLA-B 57:01 screening using the rs2395029 and rs3093726 haplotype genotyping as surrogate marker for this HLA-B. The assay provides accurate, cost-effective and rapid detection of this haplotype. It can be applied for ABC hypersensitivity screening of the Thai population before initiating treatment with ABC. © 2014 John Wiley & Sons Ltd.Mahidol UniversityMedicinePharmacology, Toxicology and PharmaceuticsArticleSCOPUS10.1111/jcpt.12175